MutaGen™: We have developed and patented a new and innovative DME technology, for any protein based product improvement (antibodies for therapy and diagnostics, antigen for in vitro diagnostic application, therapeutic proteins, and industrial enzymes)
MutalBanks: Using our DME technology, we have generated highly diverse human monoclonal antibody libraries. Antibody leads can be isolated from MutalBanks by library screening then matured by MutaGen (improvement of affinity, specificity) for improved functionality.
MilleMab: Our new comprehensive platform includes cloning, humanisation, optimisation and Immunogenicity risk limitation, when starting from a rodent MAb.
CPPI: Cytoplasmic Protein Protein Interaction. Our yeast based screening system is dedicated to protein-protein interaction detection and drug discovery (peptides, intrabodies).
Intellectual Property
MilleGen antibody discovery platform is covered by 5 patents:
